• Home
  • Submission
    • WMO applicable
    • Non WMO research
    • Approval Board of Directors UMCG
    • Biobank
  • Topics
    • Adverse Events (SAEs, SUSARs, SADEs, etc.)
    • Recruiting and informing the potential subject.
    • Research with minors and incapacitated subjects
    • The role of the treating physician and investigator
  • Documents
  • Information & Contact
    • METc – bureau
    • Composition METc UMCG
    • METc UMCG meetings
    • METc UMCG Fee
    • More practical information
  • FAQ
  • News
    • Meeting dates 2021
    • Brexit and possible consequences for clinical research
    • Clinical Trial Regulation expected to apply from December 2021
    • New template Subject Information Sheet is mandatory from November 2020.
    • CCMO will be the competent authority for clinical investigations with medical devices
    • Modified procedure for submitting local feasibility declaration
    • What is the impact of the GDPR on the informed consent letter?
    • Conditions for (re)starting clinical research in healthcare institutions and CRUs aligned
  • English
    • Dutch
Menu
  • Home
  • Submission
    • WMO applicable
    • Non WMO research
    • Approval Board of Directors UMCG
    • Biobank
  • Topics
    • Adverse Events (SAEs, SUSARs, SADEs, etc.)
    • Recruiting and informing the potential subject.
    • Research with minors and incapacitated subjects
    • The role of the treating physician and investigator
  • Documents
  • Information & Contact
    • METc – bureau
    • Composition METc UMCG
    • METc UMCG meetings
    • METc UMCG Fee
    • More practical information
  • FAQ
  • News
    • Meeting dates 2021
    • Brexit and possible consequences for clinical research
    • Clinical Trial Regulation expected to apply from December 2021
    • New template Subject Information Sheet is mandatory from November 2020.
    • CCMO will be the competent authority for clinical investigations with medical devices
    • Modified procedure for submitting local feasibility declaration
    • What is the impact of the GDPR on the informed consent letter?
    • Conditions for (re)starting clinical research in healthcare institutions and CRUs aligned
  • English
    • Dutch
Search
Close

Approval Board of Directors UMCG

Medical scientific research executed in more than one institution in the Netherlands simultaneously is called a multicentre research. Based on the Research Declaration, the central Ethics Committee grants approval for every participating centre. After the central approval, the Board of Directors of the other institutions will send a final approval letter. This procedure is described in the CCMO External  Review Directive 2012.

Approval by Central Ethics Committee for the UMCG

What? A Research Declaration, signed by the head of the Department, must be sent to the Central Ethics Committee by the (principal) investigator in the UMCG or the applicant. The resume of the (principal) investigator in the UMCG must be attached and, if applicable, a certificate of the subject insurance of the UMCG, unless exemption of a subject insurance is granted. A certificate of the general liability insurance is not necessary.

The application for approval of a participating centre can be submitted simultaneously with the primary application to the central ethics committee or after primary approval has been granted.

Who? The coordinating investigator (applicant) handling the primary application, is responsible for submission of the (additional) documentation and amendment(s) to the central ethics committee.

Where? The application for the approval of (the addition of) the UMCG as participating centre must be submitted to the central ethics committee as a substantial amendment.

Approval Board of Directors UMCG

What? When the central reviewing committee has approved the amendment, the Board of Directors must give their approval for execution of the research. Before this approval is granted,  administrative oversight by the METc Bureau takes place: Is the research listed in the UMCG Research Registry? Are the relevant documents submitted? Have all the for this research relevant and necessary person(s) or departments been informed? For instance, participation of the hospital pharmacy is often required for medical research with (study) drugs.

Who? The coordinating investigator (applicant) submits the relevant documents on a data carrier, such as a USB-drive or CD-ROM, accompanied by a signed application letter which lists the documents being submitted. This should include at least:

  • the (primary) approval letter of the reviewing ethics committee and the documents listed therein;
  • (if applicable) the additional approval letter of the central ethics committee on the participation of the UMCG, the Research Declaration and the resume of the principal investigator in the UMCG;
  • the informed consent letter and informed consent form which will be used in the UMCG;
  • (if applicable) a final and signed clinical trial agreement between the UMCG and the sponsor;

The informed consent letter should at least mention the correct contact details of the (principal) investigator(s) in the UMCG.

Where? The administrative oversight is handled by the METc Bureau on behalf of the Board of Directors. The relevant documents for this application can be submitted to the METc Bureau.

Questions? Do you have any questions? Please don’t hesitate to contact one of the employees of the METc Bureau secretariat.

  • Home
  • Submission
  • Topics
  • FAQ
  • Documents
  • Information & contact
Menu
  • Home
  • Submission
  • Topics
  • FAQ
  • Documents
  • Information & contact

POWERED BY Wild Sea 2020